Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 1298473, 18 pages
http://dx.doi.org/10.1155/2016/1298473
Review Article

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications

Biocon Research Limited, Research & Development, Bangalore, Karnataka 560099, India

Received 4 March 2016; Revised 9 June 2016; Accepted 12 June 2016

Academic Editor: Kurt Blaser

Copyright © 2016 Anshu Kuriakose et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. N. Jensen, “Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry,” Current Opinion in Chemical Biology, vol. 8, no. 1, pp. 33–41, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. N. Burska, L. Hunt, M. Boissinot et al., “Autoantibodies to posttranslational modifications in rheumatoid arthritis,” Mediators of Inflammation, vol. 2014, Article ID 492873, 19 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Jenkins, “Modifications of therapeutic proteins: challenges and prospects,” Cytotechnology, vol. 53, no. 1–3, pp. 121–125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. M. C. van Beers and M. Bardor, “Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins,” Biotechnology Journal, vol. 7, no. 12, pp. 1473–1484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Casadevall, “Antibodies against rHuEPO: native and recombinant,” Nephrology Dialysis Transplantation, vol. 17, supplement 5, pp. 42–47, 2002. View at Google Scholar · View at Scopus
  6. I. Mukovozov, T. Sabljic, G. Hortelano, and F. A. Ofosu, “Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins,” Thrombosis and Haemostasis, vol. 99, no. 5, pp. 874–882, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. K. Ghazavi and G. A. Johnston, “Insulin allergy,” Clinics in Dermatology, vol. 29, no. 3, pp. 300–305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. I. C. MacDougall, S. D. Roger, A. De Francisco et al., “Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights,” Kidney International, vol. 81, no. 8, pp. 727–732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Jolicoeur and R. L. Tacey, “Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach,” Bioanalysis, vol. 4, no. 24, pp. 2959–2970, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. G. Jacquemin and J.-M. R. Saint-Remy, “Factor VIII immunogenicity,” Haemophilia, vol. 4, no. 4, pp. 552–557, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. U. Rosenschein, R. Lenz, J. Radnay, T. Ben Tovim, and L. A. Rozenszajn, “Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction,” Israel Journal of Medical Sciences, vol. 27, no. 10, pp. 541–545, 1991. View at Google Scholar · View at Scopus
  12. J. Li, C. Yang, Y. Xia et al., “Thrombocytopenia caused by the development of antibodies to thrombopoietin,” Blood, vol. 98, no. 12, pp. 3241–3248, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Shankar, C. Pendley, and K. E. Stein, “A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs,” Nature Biotechnology, vol. 25, no. 5, pp. 555–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. L.-C. Lim, “Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure,” Hematology, vol. 10, no. 3, pp. 255–259, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Casadevall, J. Nataf, B. Viron et al., “Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin,” The New England Journal of Medicine, vol. 346, no. 7, pp. 469–475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Ragnhammar and M. Wadhwa, “Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy,” Medical Oncology, vol. 13, no. 3, pp. 161–166, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. C. Q. Zang, D. Yang, J. Hong, M. V. Tejada-Simon, V. M. Rivera, and J. Z. Zhang, “Immunoregulation and blocking antibodies induced by interferon beta treatment in MS,” Neurology, vol. 55, no. 3, pp. 397–404, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. V. R. Dharnidharka, C. Takemoto, B. M. Ewenstein, S. Rosen, and H. W. Harris, “Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B,” Pediatric Nephrology, vol. 12, no. 8, pp. 654–657, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. H.-P. Hartung, F. Munschauer III, and H. Schellekens, “Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference,” European Journal of Neurology, vol. 12, no. 8, pp. 588–601, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis, “Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction,” Current Pharmaceutical Biotechnology, vol. 3, no. 4, pp. 349–360, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. G. Tovey and C. Lallemand, “Immunogenicity and other problems associated with the use of biopharmaceuticals,” Therapeutic Advances in Drug Safety, vol. 2, no. 3, pp. 113–128, 2011. View at Publisher · View at Google Scholar
  22. G. Schernthaner, “Immunogenicity and allergenic potential of animal and human insulins,” Diabetes Care, vol. 16, supplement 3, pp. 155–165, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner, “Immunological responses to exogenous insulin,” Endocrine Reviews, vol. 28, no. 6, pp. 625–652, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. F. A. Harding, M. M. Stickler, J. Razo, and R. B. DuBridge, “The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions,” mAbs, vol. 2, no. 3, pp. 256–265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. N. K. Bender, C. E. Heilig, B. Dröll, J. Wohlgemuth, F.-P. Armbruster, and B. Heilig, “Immunogenicity, efficacy and adverse events of adalimumab in RA patients,” Rheumatology International, vol. 27, no. 3, pp. 269–274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. T. R. D. J. Radstake, M. Svenson, A. M. Eijsbouts et al., “Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 11, pp. 1739–1745, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. R. L. West, Z. Zelinkova, G. J. Wolbink, E. J. Kuipers, P. C. F. Stokkers, and C. J. van der Woude, “Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 9, pp. 1122–1126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Coles, “Alemtuzumab therapy for multiple sclerosis,” Neurotherapeutics, vol. 10, no. 1, pp. 29–33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Furie, W. Stohl, E. M. Ginzler et al., “Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 10, no. 5, article R109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Dhimolea, “Canakinumab,” mAbs, vol. 2, no. 1, pp. 3–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. D.-Y. Chen, Y.-M. Chen, W.-T. Hung et al., “Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment,” Annals of the Rheumatic Diseases, vol. 74, no. 12, pp. 2261–2264, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Chovel-Sella, R. Karplus, T. Sella, and H. Amital, “Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis,” Israel Medical Association Journal, vol. 14, no. 6, pp. 390–394, 2012. View at Google Scholar · View at Scopus
  33. I. Zidi, A. Bouaziz, W. Mnif, A. Bartegi, F. A. Al-Hizab, and N. B. Amor, “Golimumab therapy of rheumatoid arthritis: an overview,” Scandinavian Journal of Immunology, vol. 72, no. 2, pp. 75–85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. N. A. Rizvi, J. Mazières, D. Planchard et al., “Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial,” The Lancet Oncology, vol. 16, no. 3, pp. 257–265, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. P. C. Taylor, E. Quattrocchi, S. Mallett, R. Kurrasch, J. Petersen, and D. J. Chang, “Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial,” Annals of the Rheumatic Diseases, vol. 70, no. 12, pp. 2119–2125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Jakobovits, R. G. Amado, X. Yang, L. Roskos, and G. Schwab, “From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice,” Nature Biotechnology, vol. 25, no. 10, pp. 1134–1143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. A. Lofgren, S. Dhandapani, J. J. Pennucci et al., “Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab,” The Journal of Immunology, vol. 178, no. 11, pp. 7467–7472, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Weeraratne, A. Chen, J. J. Pennucci et al., “Immunogenicity of panitumumab in combination chemotherapy clinical trials,” BMC Clinical Pharmacology, vol. 11, article 17, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Khoja, M. O. Butler, S. P. Kang, S. Ebbinghaus, and A. M. Joshua, “Pembrolizumab,” Journal for ImmunoTherapy of Cancer, vol. 3, article 36, 2015. View at Publisher · View at Google Scholar
  40. C. C. Mok, “Rituximab for the treatment of rheumatoid arthritis: an update,” Drug Design, Development and Therapy, vol. 8, pp. 87–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Karle, S. Spindeldreher, and F. Kolbinger, “Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity,” mAbs, vol. 8, no. 3, pp. 536–550, 2016. View at Publisher · View at Google Scholar
  42. H.-Y. Chiu, T. W. Chu, Y.-P. Cheng, and T.-F. Tsai, “The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab,” PLoS ONE, vol. 10, no. 11, Article ID e0142930, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. M. S. Raben, “Treatment of a pituitary dwarf with human growth hormone,” The Journal of Clinical Endocrinology and Metabolism, vol. 18, no. 8, pp. 901–903, 1958. View at Publisher · View at Google Scholar · View at Scopus
  44. W. V. Moore and P. Leppert, “Role of aggregated human growth hormone (hGH) in development of antibodies to hGH,” Journal of Clinical Endocrinology and Metabolism, vol. 51, no. 9, pp. 691–697, 1980. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Van Cutsem, S. Siena, Y. Humblet et al., “An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy,” Annals of Oncology, vol. 19, no. 1, pp. 92–98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Gogolák, B. Réthi, G. Hajas, and É. Rajnavölgyi, “Targeting dendritic cells for priming cellular immune responses,” Journal of Molecular Recognition, vol. 16, no. 5, pp. 299–317, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd, and R. A. Dwek, “The impact of glycosylation on the biological function and structure of human immunoglobulins,” Annual Review of Immunology, vol. 25, pp. 21–50, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. D. M. Sheeley, B. M. Merrill, and L. C. E. Taylor, “Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal α-linked galactose,” Analytical Biochemistry, vol. 247, no. 1, pp. 102–110, 1997. View at Publisher · View at Google Scholar · View at Scopus
  49. C. H. Chung, B. Mirakhur, E. Chan et al., “Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3- galactose,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1109–1117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Eggleton, R. Haigh, and P. G. Winyard, “Consequence of neo-antigenicity of the ‘altered self’,” Rheumatology, vol. 47, no. 5, pp. 567–571, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. J. C. Egrie and J. K. Browne, “Development and characterization of novel erythropoiesis stimulating protein (NESP),” British Journal of Cancer, vol. 84, supplement 1, pp. 3–10, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. D. T. Mytych, T. E. Barger, C. King et al., “Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing,” Journal of Immunological Methods, vol. 382, no. 1-2, pp. 129–141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Rossert, N. Casadevall, and K.-U. Eckardt, “Anti-erythropoietin antibodies and pure red cell aplasia,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 398–406, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Seidl, O. Hainzl, M. Richter et al., “Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity,” Pharmaceutical Research, vol. 29, no. 6, pp. 1454–1467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. D. K. Weeraratne, A. J. Kuck, N. Chirmule, and D. T. Mytych, “Measurement of anti-erythropoiesis-stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell aplasia,” Clinical and Vaccine Immunology, vol. 20, no. 1, pp. 46–51, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Antonelli and F. Dianzani, “Development of antibodies to interferon beta in patients: technical and biological aspects,” European Cytokine Network, vol. 10, no. 3, pp. 413–422, 1999. View at Google Scholar · View at Scopus
  57. C. L. Wagner, A. Schantz, E. Barnathan et al., “Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade,” Developments in biologicals, vol. 112, pp. 37–53, 2003. View at Google Scholar · View at Scopus
  58. V. Jawa, L. P. Cousens, M. Awwad, E. Wakshull, H. Kropshofer, and A. S. De Groot, “T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation,” Clinical Immunology, vol. 149, pp. 534–555, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. M. G. Jacquemin, B. G. Desqueper, A. Benhida et al., “Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor,” Blood, vol. 92, no. 2, pp. 496–506, 1998. View at Google Scholar · View at Scopus
  60. J. Oldenburg, J. Schröder, C. Schmitt, H. H. Brackmann, and R. Schwaab, “Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype,” Thrombosis and Haemostasis, vol. 79, no. 2, pp. 452–453, 1998. View at Google Scholar · View at Scopus
  61. M. Franchini and P. M. Mannucci, “Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice,” British Journal of Clinical Pharmacology, vol. 72, no. 4, pp. 553–562, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Schwaab, H.-H. Brackmann, C. Meyer et al., “Haemophilia A: mutation type determines risk of inhibitor formation,” Thrombosis and Haemostasis, vol. 74, no. 6, pp. 1402–1406, 1995. View at Google Scholar · View at Scopus
  63. G. Kemball-Cook, E. G. D. Tuddenham, and A. I. Wacey, “The factor VIII structure and mutation resource site: HAMSTeRS version 4,” Nucleic Acids Research, vol. 26, no. 1, pp. 216–219, 1998. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Oldenburg, O. El-Maarri, and R. Schwaab, “Inhibitor development in correlation to factor VIII genotypes,” Haemophilia, vol. 8, supplement 2, pp. 23–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. G. S. Pandey, C. Yanover, L. M. Miller-Jenkins et al., “Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A,” Nature Medicine, vol. 19, no. 10, pp. 1318–1324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Young, H. Inaba, L. W. Hoyer, M. Higuchi, H. H. Kazazian Jr., and S. E. Antonarakis, “Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene,” American Journal of Human Genetics, vol. 60, no. 3, pp. 565–573, 1997. View at Google Scholar · View at Scopus
  67. J. Oldenburg, J. K. Picard, R. Schwaab, H. H. Brackmann, E. G. D. Tuddenham, and E. Simpson, “HLA genotype of patients with severe haemophilia a due to intron 22 inversion with and without inhibitors of factor VIII,” Thrombosis and Haemostasis, vol. 77, no. 2, pp. 238–242, 1997. View at Google Scholar · View at Scopus
  68. I. Scharrer, G. L. Bray, and O. Neutzling, “Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates,” Haemophilia, vol. 5, no. 3, pp. 145–154, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Astermark, “Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors,” Haemophilia, vol. 12, supplement 6, pp. 8–14, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Astermark, E. Berntorp, G. C. White et al., “The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development,” Haemophilia, vol. 7, no. 3, pp. 267–272, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Singh, S. Singh, and J. W. Lillard, “Past, present, and future technologies for oral delivery of therapeutic proteins,” Journal of Pharmaceutical Sciences, vol. 97, no. 7, pp. 2497–2523, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. S. K. Singh, “Impact of product-related factors on immunogenicity of biotherapeutics,” Journal of Pharmaceutical Sciences, vol. 100, no. 2, pp. 354–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Peng, P. Gaitonde, M. P. Kosloski, R. D. Miclea, P. Varma, and S. V. Balu-Iyer, “Effect of route of administration of human recombinant factor VIII on its immunogenicity in hemophilia A mice,” Journal of Pharmaceutical Sciences, vol. 98, no. 12, pp. 4480–4484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Perini, A. Facchinetti, P. Bulian et al., “Interferon-β (INF-β) antibodies in interferon-β1a- and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo,” European Cytokine Network, vol. 12, no. 1, pp. 56–61, 2001. View at Google Scholar
  75. S. E. Fineberg, T. Kawabata, D. Finco-Kent, C. Liu, and A. Krasner, “Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3287–3294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Hermansen, T. Rönnemaa, A. H. Petersen, S. Bellaire, and U. Adamson, “Intensive Therapy with Inhaled Insulin via the AERx Insulin Diabetes Management System: a 12-week proof-of-concept trial in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 1, pp. 162–167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Schellekens, “Factors influencing the immunogenicity of therapeutic proteins,” Nephrology Dialysis Transplantation, vol. 20, supplement 6, pp. vi3–vi9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. E.-M. Jahn and C. K. Schneider, “How to systematically evaluate immunogenicity of therapeutic proteins—regulatory considerations,” New Biotechnology, vol. 25, no. 5, pp. 280–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. A. S. Rosenberg and A. S. Worobec, “A risk-based approach to immunogenicity concerns of therapeutic protein products, part 2: considering host-specific and product-specific factors impacting immunogenicity,” BioPharm International, vol. 17, no. 12, pp. 34–42, 2004. View at Google Scholar · View at Scopus
  80. I. Hwang and S. Park, “Computational design of protein therapeutics,” Drug Discovery Today: Technologies, vol. 5, no. 2-3, pp. e43–e48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. M. P. Baker and T. D. Jones, “Identification and removal of immunogenicity in therapeutic proteins,” Current Opinion in Drug Discovery and Development, vol. 10, no. 2, pp. 219–227, 2007. View at Google Scholar · View at Scopus
  82. Q. Vos, A. Lees, Z.-Q. Wu, C. M. Snapper, and J. J. Mond, “B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms,” Immunological Reviews, vol. 176, pp. 154–170, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. X. Zhong and J. F. Wright, “Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications,” International Journal of Cell Biology, vol. 2013, Article ID 273086, 19 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Jefferis and M.-P. Lefranc, “Human immunoglobulin allotypes: possible implications for immunogenicity,” mAbs, vol. 1, no. 4, pp. 332–338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Seo and K.-J. Lee, “Post-translational modifications and their biological functions: proteomic analysis and systematic approaches,” Journal of Biochemistry and Molecular Biology, vol. 37, no. 1, pp. 35–44, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. R. J. Solá and K. Griebenow, “Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy,” BioDrugs, vol. 24, no. 1, pp. 9–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Walsh, “Biopharmaceutical benchmarks 2010,” Nature Biotechnology, vol. 28, no. 9, pp. 917–924, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. Y. Vugmeyster, X. Xu, F. P. Theil, L. A. Khawli, and M. W. Leach, “Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges,” World Journal of Biological Chemistry, vol. 3, no. 4, pp. 73–92, 2012. View at Google Scholar
  89. S. Hermeling, D. J. A. Crommelin, H. Schellekens, and W. Jiskoot, “Structure-immunogenicity relationships of therapeutic proteins,” Pharmaceutical Research, vol. 21, no. 6, pp. 897–903, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Sheridan, “Commercial interest grows in glycan analysis,” Nature Biotechnology, vol. 25, no. 2, pp. 145–146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. J.-Y. Park, M.-R. Park, D.-N. Kwon et al., “Alpha 1,3-galactosyltransferase deficiency in pigs increases sialyltransferase activities that potentially raise non-gal xenoantigenicity,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 560850, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. U. Galili, “The α-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy,” Immunology and Cell Biology, vol. 83, no. 6, pp. 674–686, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. V. Padler-Karavani and A. Varki, “Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk,” Xenotransplantation, vol. 18, no. 1, pp. 1–5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. K. A. van Schie, G.-J. Wolbink, and T. Rispens, “Cross-reactive and pre-existing antibodies to therapeutic antibodies—effects on treatment and immunogenicity,” mAbs, vol. 7, no. 4, pp. 662–671, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Qian, T. Liu, L. Yang, A. Daus, R. Crowley, and Q. Zhou, “Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion,” Analytical Biochemistry, vol. 364, no. 1, pp. 8–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. X. Xu, H. Nagarajan, N. E. Lewis et al., “The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line,” Nature Biotechnology, vol. 29, no. 8, pp. 735–741, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Ghaderi, R. E. Taylor, V. Padler-Karavani, S. Diaz, and A. Varki, “Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins,” Nature Biotechnology, vol. 28, no. 8, pp. 863–867, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. E. Maeda, S. Kita, M. Kinoshita, K. Urakami, T. Hayakawa, and K. Kakehi, “Analysis of nonhuman N-glycans as the minor constituents in recombinant monoclonal antibody pharmaceuticals,” Analytical Chemistry, vol. 84, no. 5, pp. 2373–2379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. A. M. Goetze, M. R. Schenauer, and G. C. Flynn, “Assessing monoclonal antibody product quality attribute criticality through clinical studies,” mAbs, vol. 2, no. 5, pp. 500–507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. A. M. Goetze, Y. D. Liu, Z. Zhang et al., “High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans,” Glycobiology, vol. 21, no. 7, pp. 949–959, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. D. Reusch and M. L. Tejada, “Fc glycans of therapeutic antibodies as critical quality attributes,” Glycobiology, vol. 25, no. 12, pp. 1325–1334, 2015. View at Publisher · View at Google Scholar
  102. F. Sallusto, M. Cella, C. Danieli, and A. Lanzavecchia, “Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products,” Journal of Experimental Medicine, vol. 182, no. 2, pp. 389–400, 1995. View at Publisher · View at Google Scholar · View at Scopus
  103. L. Runkel, W. Meier, R. B. Pepinsky et al., “Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β),” Pharmaceutical Research, vol. 15, no. 4, pp. 641–649, 1998. View at Publisher · View at Google Scholar · View at Scopus
  104. A. J. Chirino and A. Mire-Sluis, “Characteristics biological products and assessing comparability following manufacturing changes,” Nature Biotechnology, vol. 22, no. 11, pp. 1383–1391, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. R. J. Harris, “Heterogeneity of recombinant antibodies: linking structure to function,” Developments in Biologicals, vol. 122, pp. 117–127, 2005. View at Google Scholar · View at Scopus
  106. M. C. Manning, D. K. Chou, B. M. Murphy, R. W. Payne, and D. S. Katayama, “Stability of protein pharmaceuticals: an update,” Pharmaceutical Research, vol. 27, no. 4, pp. 544–575, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. R. Torosantucci, O. Mozziconacci, V. Sharov, C. Schöneich, and W. Jiskoot, “Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via michael addition to tyrosine oxidation products,” Pharmaceutical Research, vol. 29, no. 8, pp. 2276–2293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. W. Chen, N. J. Ede, D. C. Jackson, J. McCluskey, and A. W. Purcell, “CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design,” The Journal of Immunology, vol. 157, no. 3, pp. 1000–1005, 1996. View at Google Scholar · View at Scopus
  109. J. L. Cleland, M. F. Powell, and S. J. Shire, “The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 10, no. 4, pp. 307–377, 1993. View at Google Scholar · View at Scopus
  110. H. A. Doyle, J. Zhou, M. J. Wolff et al., “Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity,” Journal of Biological Chemistry, vol. 281, no. 43, pp. 32676–32683, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. A. S. Rosenberg, “Effects of protein aggregates: an immunologic perspective,” AAPS Journal, vol. 8, no. 3, pp. E501–E507, 2006. View at Publisher · View at Google Scholar · View at Scopus
  112. H. Schellekens, “Biosimilar therapeutics—what do we need to consider?” NDT Plus, vol. 2, supplement 1, pp. i27–i36, 2009. View at Publisher · View at Google Scholar
  113. M. Sauerborn, V. Brinks, W. Jiskoot, and H. Schellekens, “Immunological mechanism underlying the immune response to recombinant human protein therapeutics,” Trends in Pharmacological Sciences, vol. 31, no. 2, pp. 53–59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Noguchi, “Structural changes induced by the deamidation and isomerization of asparagine revealed by the crystal structure of Ustilago sphaerogena ribonuclease U2B,” Biopolymers, vol. 93, no. 11, pp. 1003–1010, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. R. Torosantucci, V. S. Sharov, M. van Beers, V. Brinks, C. Schöneich, and W. Jiskoot, “Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity,” Molecular Pharmaceutics, vol. 10, no. 6, pp. 2311–2322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Basu, K. Yang, M. Wang et al., “Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation,” Bioconjugate Chemistry, vol. 17, no. 3, pp. 618–630, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. J. S. Bee, S. A. Nelson, E. Freund, J. F. Carpenter, and T. W. Randolph, “Precipitation of a monoclonal antibody by soluble tungsten,” Journal of Pharmaceutical Sciences, vol. 98, no. 9, pp. 3290–3301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. P. Hong, S. Koza, and E. S. P. Bouvier, “A review size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates,” Journal of Liquid Chromatography and Related Technologies, vol. 35, no. 20, pp. 2923–2950, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. G. Shankar, E. Shores, C. Wagner, and A. Mire-Sluis, “Scientific and regulatory considerations on the immunogenicity of biologics,” Trends in Biotechnology, vol. 24, no. 6, pp. 274–280, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. J. Wang, J. Lozier, G. Johnson et al., “Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment,” Nature Biotechnology, vol. 26, no. 8, pp. 901–908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. V. Brinks, W. Jiskoot, and H. Schellekens, “Immunogenicity of therapeutic proteins: the use of animal models,” Pharmaceutical Research, vol. 28, no. 10, pp. 2379–2385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Hermeling, H. Schellekens, D. J. A. Crommelin, and W. Jiskoot, “Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity?” Pharmaceutical Research, vol. 20, no. 12, pp. 1903–1907, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. M. M. C. van Beers, M. Sauerborn, F. Gilli, V. Brinks, H. Schellekens, and W. Jiskoot, “Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice,” Pharmaceutical Research, vol. 27, no. 9, pp. 1812–1824, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. A. S. De Groot and W. Martin, “Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics,” Clinical Immunology, vol. 131, no. 2, pp. 189–201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Hermeling, L. Aranha, J. M. A. Damen et al., “Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b,” Pharmaceutical Research, vol. 22, no. 12, pp. 1997–2006, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. M. M. C. van Beers, M. Sauerborn, F. Gilli, V. Brinks, H. Schellekens, and W. Jiskoot, “Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice,” Pharmaceutical Research, vol. 28, no. 10, pp. 2393–2402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. P. Gaitonde and S. V. Balu-Iyer, “In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting,” in Drug Design and Discovery, vol. 716 of Methods in Molecular Biology, pp. 267–280, Springer, Berlin, Germany, 2011. View at Publisher · View at Google Scholar
  128. K. D. Ratanji, J. P. Derrick, R. J. Dearman, and I. Kimber, “Immunogenicity of therapeutic proteins: influence of aggregation,” Journal of Immunotoxicology, vol. 11, no. 2, pp. 99–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. M. K. Joubert, M. Hokom, C. Eakin et al., “Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses,” The Journal of Biological Chemistry, vol. 287, no. 30, pp. 25266–25279, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. T. W. Tobery, S. A. Dubey, K. Anderson et al., “A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV type 1 gag vaccinated human subjects,” AIDS Research and Human Retroviruses, vol. 22, no. 11, pp. 1081–1090, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. M. G. Tovey, J. Legrand, and C. Lallemand, “Overcoming immunogenicity associated with the use of biopharmaceuticals,” Expert Review of Clinical Pharmacology, vol. 4, no. 5, pp. 623–631, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. E. Koren, A. S. De Groot, V. Jawa et al., “Clinical validation of the ‘in silico’ prediction of immunogenicity of a human recombinant therapeutic protein,” Clinical Immunology, vol. 124, no. 1, pp. 26–32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. X. Wang, T. K. Das, S. K. Singh, and S. Kumar, “Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies,” mAbs, vol. 1, no. 3, pp. 254–267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. R. Jefferis, “Aggregation, immune complexes and immunogenicity,” mAbs, vol. 3, no. 6, pp. 503–504, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. S. Maier, C. H. Chung, M. Morse et al., “A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions,” Cancer Medicine, vol. 4, no. 1, pp. 36–42, 2015. View at Publisher · View at Google Scholar
  136. Y. H. Messinger, N. J. Mendelsohn, W. Rhead et al., “Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease,” Genetics in Medicine, vol. 14, no. 1, pp. 135–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. C. Ma, V. Huang, D. K. Fedorak et al., “Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 40, no. 9, pp. 1044–1055, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. S.-L. Wang, S. Hauenstein, L. Ohrmund et al., “Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay,” Journal of Pharmaceutical and Biomedical Analysis, vol. 78-79, pp. 39–44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. R. Jefferis, “Posttranslational modifications and the immunogenicity of biotherapeutics,” Journal of Immunology Research, vol. 2016, Article ID 5358272, 15 pages, 2016. View at Publisher · View at Google Scholar
  140. H. C. Ebbers, S. A. Crow, A. G. Vulto, and H. Schellekens, “Interchangeability, immunogenicity and biosimilars,” Nature Biotechnology, vol. 30, no. 12, pp. 1186–1190, 2012. View at Publisher · View at Google Scholar · View at Scopus
  141. G. M. Peterson, “Generic substitution: a need for clarification,” British Journal of Clinical Pharmacology, vol. 71, no. 6, pp. 966–968, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. G. Walsh, “Post-translational modifications of protein biopharmaceuticals,” Drug Discovery Today, vol. 15, no. 17-18, pp. 773–780, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. A. Colbert, A. Umble-Romero, S. Prokop et al., “Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs,” mAbs, vol. 6, no. 5, pp. 1178–1189, 2014. View at Publisher · View at Google Scholar · View at Scopus